Artivion Inc. (NYSE:AORT) shares climbed 4.2% on Tuesday following Jefferies’ decision to begin coverage with a Buy rating and a $31 price target. The Wall Street firm frames the cardiovascular device maker as a key beneficiary of growth in aortic surgery, underpinned by an expanding product lineup and margin-accretive new offerings.
Jefferies analyst Michael Sarcone singled out two products central to the thesis: the AMDS hybrid prosthesis and the Nexus endovascular stent graft. Based on conversations with healthcare providers, Sarcone expects both devices to see meaningful adoption in the U.S. over time, driven by product differentiation and existing unmet clinical needs. The analyst emphasized that each device carries a gross-margin-accretive profile that should help lift operating profitability and support growth in earnings before interest, taxes, depreciation and amortization.
That commercial trajectory ties into Artivion’s longer-term operational ambitions. The company has set targets that call for at least 10% average annual revenue growth and at least 20% EBITDA growth. Jefferies translated those targets into explicit revenue forecasts of $547 million for 2027 and $617 million for 2028, which the firm says correspond to constant-currency growth of roughly 11% and 13% in those years respectively. Jefferies notes these projected growth rates sit above consensus expectations.
Valuation is also part of Jefferies’ investment case. The firm’s work values Artivion at about 12 times EBITDA, a multiple that Sarcone describes as a discount to many medical technology peers. He characterizes that lower multiple as an "attractive entry point" for investors ahead of several upcoming commercial milestones, including the planned U.S. launch of the Nexus device in early 2027.
Jefferies’ initiation emphasizes the structural growth drivers through 2027 rather than short-term quarterly volatility. The firm argues that a combination of pipeline momentum, operating leverage on margins and the prospect of multiple expansion underpin the view that Artivion can deliver sustained outperformance over coming years, provided execution aligns with the assumptions embedded in its forecasts.
Questions remain, and the analyst’s commentary highlights a focus on what will validate U.S. adoption of AMDS and Nexus as the market watches for meaningful uptake and margin translation into EBITDA. For now, Jefferies’ initial coverage establishes a framework of revenue and profitability targets, a relative valuation backdrop and a timetable tied to the Nexus U.S. launch as central elements of the case for the stock.